SGLT2抑制剂治疗糖尿病研究进展  

Research on type 2 sodium glucose co-transporters in diabetes treatment

作　　者：丁海峰[1] 曹永兵[1] 安毛毛[1] 贾鑫明[1] 姜远英[1] 

机构地区：[1]第二军医大学药学院新药研究中心,上海200433

出　　处：《药学实践杂志》2011年第2期89-92,116,共5页Journal of Pharmaceutical Practice

摘　　要：近年来,钠-葡萄糖协同转运蛋白2(type 2 sodium glucose co-transporters,SGLT2)抑制剂作为一种新型的治疗糖尿病药物成为研究热点。SGLT2在肾近端小管葡萄糖重吸收中起着非常重要的作用;抑制肾脏SGLT2可以促进Ⅱ型糖尿病人尿糖的排泄,使其血糖恢复正常而不会有低血糖的风险。临床实验表明,SGLT2抑制剂对Ⅱ型糖尿病的治疗效果明显,且具有降低体重、无低血糖风险等优点,目前,许多SGLT2抑制剂已经进入临床评价后期。In the last few years,inhibitors of the type 2 sodium glucose co-transporters（SGLT2） had been the subject of novel approach to treating diabetes.SGLT2 played a major role in physiology of glucose reabsorption from proximal part of kidney.The blockade of SGLT2 in the kidney had the potential to prompts urinary excretion of glucose and promotes normalization of blood glucose without hypoglycemia in the setting of type 2 diabetes.Clinical trails showed that their efficacy in the treatment of type 2 diabetes was promising; Weight loss and very low risk of hypoglycemia were the potential benefits of these inhibitors.Some of these inhibitors had been developed and advanced to late phase clinical testing

关 键 词：Ⅱ型糖尿病 钠-葡萄糖协同转运蛋白 抑制剂 

分 类 号：R977[医药卫生—药品]